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Occupational asthma (OA) is characterized by allergic airway inflammation and hyperresponsiveness, leading
to progressive airway remodeling and a concomitant decline in lung function. The management of OA remains
suboptimal in clinical practice. Thus, establishing effective therapies might overcome the natural history of the
disease. We evaluated the ability of human adipose-tissue-derived mesenchymal stem cells (hASCs), either
unmodified or engineered to secrete the IL-33 decoy receptor sST2, to attenuate the inflammatory and respi-
ratory symptoms in a previously validated mouse model of OA to ammonium persulfate (AP). Twenty-four
hours after a dermal AP sensitization and intranasal challenge regimen, the animals received intravenously
1 · 106 cells (either hASCs or hASCs overexpressing sST2) or saline and were analyzed at 1, 3, and 6 days after
treatment. The infused hASCs induced an anti-inflammatory and restorative program upon reaching the AP-
injured, asthmatic lungs, leading to early reduction of neutrophilic inflammation and total IgE production,
preserved alveolar architecture with nearly absent lymphoplasmacytic infiltrates, negligible smooth muscle hy-
perplasia/hypertrophy in the peribronchiolar areas, and baseline airway hyperreactivity (AHR) to methacholine.
Local sST2 overexpression barely increased the substantial efficacy displayed by unmodified hASCs. Thus,
hASCs may represent a viable multiaction therapeutic capable to adequately respond to the AP-injured lung
environment by resolving inflammation, tissue remodeling, and bronchial hyperresponsiveness typical of OA.
Introduction
In industrialized countries occupational asthma (OA)is the leading cause of respiratory diseases from occupa-
tional origin, and it can affect up to 30 per 100,000 inhabi-
tants [1]. This condition accounts for 10% of people with
asthma, causing severe respiratory pathology in young indi-
viduals and, therefore, involves a major socioeconomic
burden. Persulfate salts used in hairdressing and cosmetics
are well-known etiological agents involved in OA. These
chemicals may be responsible for up to 5.8% of all cases of
OA [2], representing the second, third, or fourth leading
cause of OA according to different reports [2,3]. The mech-
anism by which persulfate salts cause OA is not well known,
although based on clinical studies most authors support an
immunologic mechanism [2,4].
Nowadays, management of OA is largely preventive and
symptomatic, aimed avoiding or reducing work exposure to
the causative agent and optimizing the standard medical
treatment with bronchodilators and inhaled glucocorticoids
[5]. Nevertheless, pharmacological treatment has proven of
limited utility [6]. Regarding OA caused by persulfate salts,
it has been observed in a small number of patients that their
condition seems to improve if they avoid exposure, although
asthma symptoms and bronchial hyperresponsiveness may
persist [7]. Therefore, a more causal intervention being able
to attenuate the immune-inflammatory process while re-
versing remodeling in the asthmatic airways should be
highly desirable to avoid the progressive decline of lung
function in these patients.
Due to their regenerative potential and recently charac-
terized immune modulatory and anti-inflammatory proper-
ties, mesenchymal stem cells (MSCs) have been proposed
as novel therapeutic agents in a wide variety of immune-
inflammatory processes leading to tissue injury, including
asthma [8,9]. Indeed, MSCs can be easily isolated from
several tissues using minimally invasive procedures. Re-
markably, fat tissue has proven a rich source of adipose-
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tissue-derived MSCs (termed ASCs) [10]. Shortly after be-
ing administered systemically, MSCs are primarily localized
into the lung due to their size (20 mm in diameter), larger
than the width of the lung microcapillaries. Additionally,
enhanced lung retention is achieved in a proinflammatory
microenvironment [11]. Finally, MSCs can be gene en-
hanced for local production of therapeutically relevant
transgenic paracrine factors [12]. Consequently, several
studies have recently reported preventive and/or therapeutic
benefit of unmodified or genetically engineered MSC
transplantation in several acute and chronic airway pathol-
ogies [13–15].
Our group has recently shown, in an OA murine model,
that inhalation of persulfate salts induces an asthmatic re-
sponse characterized by neutrophilic inflammation, raised
serum IgE levels, increased T and B lymphocyte presence
and activity in auricular and cervical draining lymph nodes,
and airway hyperresponsiveness [16]. In the present study
we have evaluated the therapeutic potential of human adi-
pose-tissue-derived mesenchymal stem cells (hASCs), either
unmodified or genetically engineered to overexpress sST2
[17]—a natural decoy receptor to IL-33 [18], key alarmin in
innate eosinophilic airway inflammation—resolving the
underlying immune-inflammatory process and the chronic
airway hyperreactivity (AHR) inherent in the validated am-
monium persulfate [(NH4)2S2O8; AP]–induced OA model.
Materials and Methods
Animals
Male BALB/c mice (*20 g, 6-week old) were obtained
from Harlan. The mice were housed in filter-top cages in a
conventional animal house with 12 h dark/light cycles and
received lightly acidified water and pelleted food (Trouw
Nutrition) ad libitum. All procedures involving mice were
reviewed and approved by the Ethical Committee of Animal
Experimentation from the Vall d’Hebron Research Institute
(Barcelona, Spain) (CEEA study No. 61/09).
Isolation and characterization of ASCs
Discarded human adipose tissue from healthy adult wo-
men undergoing elective lipoaspiration was used as the
source of hASCs, under the Institutional Ethics Committee
approval as described elsewhere [17,19]. The raw lipoas-
pirate (200 mL) was washed extensively in phosphate-
buffered saline (PBS) and incubated in PBS containing
0.075% type II collagenase (Life Technologies) at 37C for
1 h to digest the extracellular matrix. The protease activity
was neutralized with Dulbecco’s modified Eagle’s medium
(DMEM; Life Technologies) plus 10% fetal bovine serum
(FBS). The resulting suspension was filtered through a 70-
mm nylon strainer; centrifuged; resuspended in a-MEM
(Life Technologies) containing 15% FBS, 1% penicillin/
streptomycin, 1% l-glutamine, and 2.5 mg/mL amphotericin
(all from Life Technologies); and seeded overnight in cul-
ture flasks (Corning, Inc.) at 37C in a 5% CO2 atmosphere.
Next day, the cell monolayer was washed once more with
PBS to remove nonadherent cells and cellular debris and
replaced with fresh medium. The cells were expanded until
80% confluence and amplified through periodic passaging
(split ratio 1:2).
Flow cytometry to assess the expression levels of differ-
ent surface markers was performed on an FACScan cyt-
ometer using CellQuest software (BD Biosciences). The
hASCs were stained with fluorescein-isothiocyanate (FITC)
or phycoerythrin (PE)–conjugated antibodies against CD44,
CD29 (Immunostep), CD90 (eBioscience), CD14, HLA-
DR, and CD34 (BD Biosciences) and the corresponding
fluorescent isotype-matched negative control antibodies
(Supplementary Fig. S1A; Supplementary Data are available
online at www.liebertpub.com/scd).
Adipocytic differentiation was induced by seeding hASCs
for 21 days in Iscove’s modified Dulbecco’s medium (IMDM;
Life Technologies) supplemented with 0.5 mM isobutyl me-
thyl xantine, 1mM hydrocortisone, and 0.1 mM indomethacin,
and visualized by Oil Red-O staining. Osteocytic differentia-
tion was induced by culturing hASCs in IMDM containing
0.1mM dexametasone, 10 mM b-glycerol phosphate, and
0.2 mM ascorbic acid for 21 days, and visualized after Alizarin
Red staining. All hASC differentiation reagents were from
Sigma-Aldrich (Supplementary Fig. S1B).
Mouse adipose-tissue-derived mesenchymal stem cells
(mASCs) were obtained from the inguinal fat pads of female
BALB/c mice, and isolated and characterized analogously to
hASCs.
Bioluminescence imaging
Mice were administered, via the lateral tail vein, 1 · 106
hASCs transduced with a bicistronic lentiviral vector (LV-
T2A) encoding the firefly luciferase (fLuc) and the EGFP
under the control of a cytomegalovirus promoter [17]. To
track fLuc-expressing hASCs, mice were intraperitoneally
injected with D-luciferin (150 mg/kg) (Promega) dissolved
in PBS and imaged at different times (ranging from 10 min
to 5 days) in an IVIS Spectrum Imaging System (Caliper
Life Sciences). Anesthesia was performed in an induction
chamber with 3% isoflurane in 100% oxygen at a flow rate
of 1.25 L/min and maintained in the IVIS system with a
2.5% of the above mixture at 0.5 L/min. Bioluminescent
signaling on the lungs was measured as integrated photons/
second. Imaging data were analyzed using the Living Image
4.1 (Caliper Life Sciences).
sST2 cloning, lentiviral vector production,
and hASC transduction
The synthesis and production of VSV-G-pseudotyped,
high-titer lentiviral particles from the bicistronic expression
vector pWPT-sST2FLAG2AEGFP (pWPT-sST2-EGFP)
and its corresponding control pWPT-EGFP have been pre-
viously described [17]. pWPT-sST2-EGFP encodes, in a 5¢
to 3¢ orientation, the C-terminus FLAG-tagged murine sST2
cDNA, the picornaviral 2A sequence for cotranslational
cleavage, and the reporter EGFP cDNA. pWPT-EGFP en-
codes only the EGFP cDNA. Both lentiviral vectors are
under control of the strong constitutive human EF-1alpha
promoter (Supplementary Fig. S2).
hASCs from passage 2–3 were transduced in suspension
with the previous lentiviral vector particles at several mul-
tiplicities of infection (MOI), ranging from 1 to 40. The
culture medium was replaced after 16 h to remove lentiviral
particles. At 48 h after transduction, the EGFP expression
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was analyzed by both flow cytometry and fluorescence mi-
croscopy. The recombinant mouse sST2 protein expres-
sion was assessed by a specific mouse T1/ST2 sandwich
enzyme-linked immunosorbent assay (ELISA; mdbiopro-
ducts) according to the manufacturer’s instructions, and by
western blot analysis using an anti-FLAG antibody [17].
The functional activity of the secreted sST2-FLAG decoy
was evaluated by assessing its ability to interfere with
proinflammatory IL-33-T1/ST2 signaling in P815 mouse
mastocytoma cells [17].
The hASCs administered to the OA mouse model were
previously transduced with the appropriate lentiviral vector
particles at an optimized MOI of 20. Both pWPT-sST2-
EGFP-transduced hASCs (hASC-sST2) and pWPT-EGFP-
transduced hASCs (hASC) reached an average of 80% – 5%
transduction efficiency. Moreover, hASC-sST2 attained a
persistent level of secreted sST2 of 35 – 15 ng/mL [17].
Mouse model of chemical-induced asthma
Schematic approach followed for the hASC-based treat-
ment of experimental OA (Fig. 1) according to the previ-
ously published model [16]. On days 0 and 7, the mice
received dermal applications of 5% AP or vehicle (DMSO)
on the dorsum of both ears (20mL). On day 14, they re-
ceived, under light anesthesia with isoflurane (Forene; Ab-
bott Laboratories), an intranasal instillation (40 mL) of 1%
AP (challenge) or vehicle (saline; PBS). Experimental
groups are as follows: DMSO/SAL–PBS and DMSO/AP–
PBS (negative control, nonasthmatic untreated mice);
DMSO/SAL–hASC, DMSO/SAL–hASC-sST2, DMSO/AP–
hASC, and DMSO/AP–hASC-sST2 (evaluation of potential
side-effects of xenogeneic hASC administration in non-
asthmatic mice); AP/AP–PBS (positive control, asthmatic
untreated mice); and AP/AP–hASC and AP/AP–hASC-sST2
(evaluation of the therapeutic effects of hASC administra-
tion in asthmatic mice). The first abbreviation identifies the
agent used for the dermal application on days 0 and 7
(sensitization), the second abbreviation identifies the agent
administered via intranasal instillation on day 14 (chal-
lenge), and the third abbreviation identifies the treatment on
day 15 [1 · 106 cells (hASC or hASC-sST2 in PBS), or PBS
alone (250 mL) via tail vein injection].
Blood retrieval, bronchoalveolar lavage,
and cell count
After the methacholine tests, the mice were deeply an-
esthetized by an intraperitoneal injection of pentobarbital
(Nembutal, Sanofi Santé Animale, CEVA). Blood was
sampled from the retro-orbital plexus; the lungs were la-
vaged, in situ, three times with 0.7 mL of sterile saline; and
the recovered fluid was pooled. Cells were counted and the
bronchoalveolar lavage fluid (BALF) was centrifuged (1000 g,
10 min). The supernatant was frozen ( - 80C) until fur-
ther analyses. For differential cell counts, 250 mL of the
resuspended cells (100,000 cells/mL) were spun (300 g,
6 min; Cytospin 3, Shandon, TechGen) onto microscope
slides, air-dried, and stained (Diff-Quik method; Medical
Diagnostics). For each sample, 500 cells were counted for
the number of macrophages, eosinophils, neutrophils, and
lymphocytes.
Immunoassays
IL-33 was measured in undiluted sera by standard ELISA
techniques, according to the manufacturer’s instructions
(Biosource). The OptEIA Mouse IgE set from Pharmingen
(BD Biosciences) was used to evaluate total serum IgE from
diluted serum (1:5 dilution). Measurements were performed
according to the manufacturer’s instructions. Further, the
concentrations of inflammatory cytokines IL-6, IL-13, IFN-
g, and IL-2 were estimated in undiluted BALF supernatants
through a luminex-based immunoassay (Millipore).
Flow cytometry analysis
The relative number of BALF mouse lymphocyte sub-
populations was assessed by flow cytometry using specific
antibodies against CD3, CD4, and CD8 (Life Technologies).
FIG. 1. Experimental design and intervention in the OA BALB/c mouse model. The initial sensitization step involves
dermal application of 5% AP or vehicle (DMSO) on the dorsum of both ears (20 mL) on days 0 and 7. On day 14, the
animals receive an intranasal instillation (40 mL) of 1% AP (challenge) or vehicle (saline). On day 15, the therapeutic
approach consists of an intravenous injection of engineered mesenchymal stem cells (1 · 106 cells; 250mL) overexpressing
either EGFP (hASC) or both sST2 and EGFP (hASC-sST2), or control vehicle (saline). Mice are then sacrificed at days 16,
18, and 21 to assess therapeutic efficacy. AP, ammonium persulfate; DMSO, dimethylsulfoxide; hASCs, human adipose-
tissue-derived mesenchymal stem cells; OA, occupational asthma.
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Histopathology and immunohistochemistry
The trachea from an independent set of DMSO/SAL–
PBS, DMSO/AP–PBS, AP/AP–PBS, AP/AP–hASC, and
AP/AP–hASC-sST2 animals undergoing neither AHR
analysis nor BAL was cannulated at day 21 after the initial
AP sensitization step, and the lungs were fixed by inflation
to total lung capacity with 1 mL of 4% paraformaldehyde.
Following overnight fixation, the lung tissue was dehydrated
with an ethanol gradient and embedded in paraffin, cut into
3-mm-thick sections, and stained with hematoxylin and eo-
sin. Images were taken with an Olympus BX41 microscope
(Olympus Life Science Research GmbH) using 40 · and
20 · objectives. To determine morphology and inflamma-
tory infiltrate, images were evaluated by a pathologist who
was blinded to the identity of the slides.
For immunohistochemistry, sliced 5-mm sections were
mounted on poly-L-lysine-coated glass slides, depar-
affinized, and rehydrated. Immunogenic retrieval was per-
formed incubating the slides in 10 mM citrate buffer (pH
6.0) for 20 min in a microwave oven. Following several
PBS-T (PBS plus 0.1% Triton X-100) washes, tissue sec-
tions were blocked by 2-h incubation in 5% goat serum
diluted in PBS-T at room temperature. Further, PBS-T-
washed sections were incubated overnight at 4C in a humid
chamber with the appropriate primary antibodies (all diluted
1:100 in PBS-T). Namely, the reporter EGFP was im-
munolocalized with a biotinylated goat polyclonal anti-GFP
(ab6658; Abcam), and the FLAG tag was identified with a
rabbit DYKDDDDK Tag antibody (Cell Signaling Technol-
ogy). Next day, for FLAG tag detection, sections were ad-
ditionally incubated with a biotin-conjugated goat anti-rabbit
IgG antibody (Invitrogen) diluted 1:1000 in PBS for 1 h at
room temperature. The endogenous peroxidase was blocked
with 3% H2O2 for 10 min in the dark. Finally, the sections
were incubated with a biotinylated horseradish peroxidase-
avidin complex (ImmunoPure ABC Peroxidase Staining
Kit; Pierce), stained with the peroxidase substrate diamino-
benzidine tetrahydrochloride (DAB; Pierce), and counter-
stained with hematoxylin. Specificity control slides were
analogously stained using nonimmune rabbit or nonimmune
goat IgG (1:100 dilution; Abcam) as primary antibodies.
RNA isolation and analysis
Mouse lung tissue was immediately frozen in liquid ni-
trogen after euthanasia. Total lung RNA was isolated using
the RNeasy Mini kit (Qiagen). After isolation, RNA samples
were DNase treated for 30 min at 37C to remove contam-
inating DNA (PE Applied Biosystems). Gene expression
analysis from hASC-treated OA (AP/AP) and control
(DMSO/SAL) mouse lung RNA was performed through
reverse transcription using the High Capacity cDNA Reverse
Transcription Kit followed by real-time quantitative TaqMan
polymerase chain reaction (TaqMan RT-qPCR; PE Applied
Biosystems). The predesigned, human gene-specific primers
and probe sets for each human gene analyzed (ICAM1;
Hs00164932_m1), PTGS2 (COX-2; Hs00153133_m1), and
(TGFB1; Hs00998133_m1), and for the endogenous house-
keeping human gene used for normalization (GUSB;
Hs99999908_m1) were obtained from Assays-on-Demand
Gene Expression Products (PE Applied Biosystems), assayed
in triplicate, and analyzed in a spectrofluorimetric thermal
cycler (ABI PRISM 7300 Sequence Detector; PE Applied
Biosystems). Data quantification was carried out through the
comparative Ct method.
Airway physiology
To assess the asthmatic profile of all mice not undergoing
histological analysis, reactivity to methacholine was evalu-
ated at days 16 and 21 after the initial AP sensitization step.
AHR was measured using a forced oscillation technique
with the Flexivent system (FlexiVent, SCIREQ). Airway
resistance (R) and elastance (E) were quantified using a
‘‘snapshot’’ protocol, as previously described [16]. For each
mouse, R and E were plotted against methacholine con-
centration (from 0 to 10 mg/mL) and the area under the
curve (AUC) was calculated.
Statistical analysis
Data are presented as mean values – SDs and were ana-
lyzed using one-way analysis of variance (ANOVA) fol-
lowed by a Dunnett post hoc test (Graphpad Prism 5.00;
Graphpad Software, Inc.). A level of P < 0.05 (two tailed)
was considered statistically significant.
Results
Intravenously transplanted hASCs localize
into the lung and undergo anti-inflammatory
activation within the AP-induced asthmatic airways
Noninvasive bioluminescent tracking of intravenously
infused fLuc-expressing hASCs into control mice revealed
their exclusive although transient homing into the lungs
[exponential decay; biological half-life (t1/2) *1.5 days]
(Supplementary Fig. S3).
Moreover, the subacute proinflammatory milieu of the
AP-sensitized and -challenged (AP/AP) mouse lungs, anal-
ogously to that recently reported for lipopolysaccharide-
induced acutely injured mouse lungs (t1/2 *3.5 days) [17],
stimulated retention and activation of circulating hASCs
(Fig. 2). Indeed, AP-induced asthmatic lung-localized hASCs
showed (1) early and sustained transcriptional upregulation
of ICAM-1 (20- to 60-fold induction), which has been found
critical for their T cell adhesive and immune modulatory
capacities [20]; and (2) late upregulation of the transcript
encoding for the inducible enzyme COX-2 (sixfold induc-
tion), whose product prostaglandin E2 increases IL-10 se-
cretion from macrophages to reduce the inflammatory
response [21]. Conversely, the Th17-inducing cytokine TGF-
b was upregulated neither at day 16 nor at day 18 after the
initial AP sensitization step.
Involvement of proinflammatory IL-33
in the OA mouse model
At the protein level, both hASCs (overexpressing EGFP)
and hASC-sST2 (overexpressing EGFP and FLAG-sST2)
were immunolocalized within the lung parenchyma in AP-
sensitized and -challenged (AP/AP) mice (Fig. 3A).
The alarmin IL-33, released by damaged epithelia, acts on
cells of both the adaptive and innate immune systems and
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has a central role driving inflammation in allergic airway
disease [18]. Accordingly, the serum IL-33 levels increased
progressively after AP sensitization and challenge in asth-
matic untreated mice (AP/AP–PBS) (Fig. 3B). In contrast,
only the asthmatic hASC-treated mice overexpressing the
IL-33 decoy receptor sST2 (AP/AP–hASC-sST2), but not
the asthmatic hASC-treated mice (AP/AP–hASC), main-
tained the baseline IL-33 level corresponding to control,
unchallenged, and untreated mice (DMSO/SAL–PBS).
Thus, at day 21 after the initial AP sensitization step, the IL-
33 values from hASC-sST2-treated (AP/AP–hASC-sST2)
mice reached statistical significance when compared with
those from both untreated (AP/AP–PBS) and hASC-treated
(AP/AP–hASC) asthmatic animals.
hASCs are able to inhibit airway neutrophilia
and IgE production in the AP-induced OA mice
The total cell count in the BALFs of OA mice did not
experience a significant variation with time after AP sensi-
tization and challenge (Fig. 4A). In contrast, the percentage
of proinflammatory neutrophils was found increased early
after AP challenge in the sensitized mice (AP/AP–PBS),
although gradually decreased to reach baseline levels by day
7 after AP challenge (day 21 after the initial AP sensitiza-
tion step) (Fig. 4B). Importantly, hASC and hASC-sST2
treatments fully reduced the early neutrophilia from the
BALFs of the asthmatic mice to baseline levels. Conversely,
we observed in the BALFs from both hASC-treated and
hASC-sST2-treated mice an increase in the percentage of
lymphocytes late after AP challenge (day 21) (Fig. 4C),
concomitantly with a complementary decrease in the per-
centage of alveolar macrophages, the major cell type present
in the BALFs of OA mice (Fig. 4D). As previously reported,
no eosinophils were recruited into the AP-treated lungs [16].
The IL-13 (Th2-type) and the IFN-g (Th1-type) cytokine
levels did not vary between groups, while IL-6 (Th17-
inducing) was reproducibly increased in the BALFs of AP-
sensitized and -challenged (AP/AP–PBS) asthmatic mice at
day 16 after the initial AP sensitization step, although it did
not reach statistical significance (Supplementary Fig. S4).
Conversely, we confirmed a significant early increase of
serum total IgE levels in the AP-sensitized and -challenged
animals (AP/AP–PBS group), which, however, could be
FIG. 2. Intrapulmonary homing and activation status of
hASCs in AP-induced OA mice. Anti-inflammatory profile
of infused hASCs in the murine lung. The relative mRNA
expression of the gene coding for the adhesion molecule
human ICAM-1, and the hASC immune modulatory genes
COX-2 and TGF-b in hASC-treated murine lung tissue
was determined by TaqMan RT-qPCR at days 16 and 18
after the initial AP sensitization step. Experimental groups
are DMSO/SAL–hASC and AP/AP–hASC. Data are rep-
resented as fold induction of the indicated gene from the
AP/AP–hASC group relative to the same gene from the
DMSO/SAL–hASC group (n = 3–4), ***P < 0.001 compared
with DMSO/SAL–hASC.
FIG. 3. Proinflammatory IL-33 involvement in the OA
mouse model. (A) Immunohistochemical localization of
pWPT-EGFP- and pWPT-sST2-EGFP-transduced hASCs
overexpressing EGFP or both murine sST2-FLAG and
EGFP, respectively, in the OA model. Representative lung
section images of AP-challenged, hASC-treated mice (AP/
AP–hASC) (upper panels), and AP-challenged, hASC-
sST2-treated mice (AP/AP–hASC-sST2) (lower panels) day
16 after the initial AP sensitization step. Arrows indicate
the brown label detection of sST2-FLAG-overexpressing
hASCs (lower left panel), and of EGFP-overexpressing
hASCs (right panels). Scale bar = 10mm. (B) Serum IL-33
dynamics in the OA mouse model. Serum IL-33 levels were
quantified by ELISA in both treated and nontreated mice
at 16, 18, and 21 days after the initial AP sensitization step.
Experimental groups are DMSO/SAL–PBS, DMSO/AP–
PBS, AP/AP–PBS, AP/AP–hASC, and AP/AP–hASC-sST2.
Values are means – SDs (n = 4–7 mice per group). *P < 0.05,
AP/AP–PBS group compared with both DMSO/SAL–PBS
and AP/AP–hASC-sST2 groups; #P < 0.05, AP/AP–hASC
group compared with both DMSO/SAL–PBS and AP/AP–
hASC-sST2 groups. SAL, saline; PBS, phosphate-buffered sa-
line; AP, ammonium persulfate; hASC, hASCs overexpressing
EGFP; hASC-sST2, hASCs overexpressing sST2 and EGFP.
Color images available online at www.liebertpub.com/scd
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fully reversed by hASC treatment (AP/AP–hASC and AP/
AP–hASC-sST2 groups) (Fig. 5).
hASCs resolve AP-induced airway hyperreactivity
in the OA mouse model
AP-sensitized and -challenged mice (AP/AP–PBS) had a
significant decline in pulmonary function [assessed by
measuring total respiratory system elastance (E) and resis-
tance (R)] compared with control nonsensitized, unchal-
lenged or with nonsensitized, AP-challenged mice (DMSO/
SAL–PBS and DMSO/AP–PBS) both at day 16 and 21 after
the initial AP sensitization step (Fig. 6). Moreover, hASC
infusion (both AP/AP–hASC and AP/AP–hASC-sST2
groups) was able to fully resolve persistent AHR. Conse-
quently, at both day 16 and 21 after the initial AP sensiti-
zation step, the mean AUC of R and E from the untreated
asthmatic group (AP/AP–PBS) was significantly higher than
the mean AUC of R and E from both hASC-treated groups
(AP/AP–hASC and AP/AP–hASC-sST2), which matched
those from the control nonasthmatic groups (DMSO/SAL–
PBS and DMSO/AP–PBS). We also discarded a potential
immune stimulatory hASC-based contribution on lung
function because the mean AUC of R and E from the control
hASC-instilled groups (DMSO/SAL–hASC and DMSO/
SAL–hASC-sST2) at day 21 was identical to that from
FIG. 4. Inflammatory cell dynamics in the bronchoalveolar lavage fluid (BALF) from the OA mouse model. Total
leukocyte counts were determined using a hemocytometer (A). Relevant BALF cell populations were further evaluated
using Diff-Quick-stained cytospin preparations, and displayed as percentage of neutrophils (B), lymphocytes (C), and
macrophages (D). Results are shown at 16, 18, and 21 days after the initial AP sensitization step. Experimental groups are
DMSO/SAL–PBS, DMSO/AP–PBS, AP/AP–PBS, AP/AP–hASC, and AP/AP–hASC-sST2. Both DMSO/SAL–hASC* and
DMSO/SAL–hASC-sST2* groups were analyzed only at day 21. Values are means – SDs (n = 6–10 mice per group). In B,
*P < 0.05 comparing AP/AP–PBS respect to all other groups; in C, ***P < 0.001 comparing AP/AP–hASC, DMSO/SAL–
hASC* and DMSO/SAL–hASC-sST2* respect to AP/AP–PBS, and #P < 0.01 comparing AP/AP–hASC-sST2 respect to AP/
AP–PBS; in (D), **P < 0.01 comparing AP/AP–hASC, DMSO/SAL–hASC* and DMSO/SAL–hASC-sST2* respect to AP/
AP–PBS. Color images available online at www.liebertpub.com/scd
FIG. 5. Total serum IgE levels in the OA mouse model.
Total IgE levels were quantified by ELISA in both treated
and nontreated mice sera (1:5 dilution). Total serum IgE at
day 16 after the initial AP sensitization step. Experimental
groups are DMSO/SAL–PBS, DMSO/AP–PBS, AP/AP–
PBS, AP/AP–hASC, and AP/AP–hASC-sST2. Values are
means – SDs (n = 5–7 mice per group). *P < 0.05 compared
with AP/AP–hASC and AP/AP–hASC-sST2 groups.
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the control untreated groups (DMSO/SAL–PBS and DMSO/
AP–PBS).
Airway histopathological alterations induced by AP
in the OA mice are ameliorated by hASC treatment
A blinded histopathological examination of lung tissue
sections from the asthmatic AP-sensitized and -challenged
mice (AP/AP–PBS) revealed marked hyperemia, moderate
leukostasis and inflammatory cell infiltration, and peri-
bronchiolar smooth muscle hyperplasia/hypertrophy (Fig. 7;
left panels). Conversely, lungs from both hASC-treated
mice (AP/AP–hASC group and AP/AP–hASC-sST2 group)
(Fig. 7; middle panels) showed preserved alveolar archi-
tecture with only slight hyperemia, few lymphoplasmacytic
infiltrates, and nearly negligible smooth muscle hyperplasia/
hypertrophy in the peribronchiolar areas, approaching the
tissue appearance from control, nonsensitized untreated
groups DMSO/SAL–PBS (Fig. 7; right panels) and DMSO/
AP–PBS (not shown). Thus, hASC treatment attenuated
perivascular and peribronchial inflammation and remodeling
in the AP-based OA mouse model (Table 1).
Immune reactivity of xenotransplanted hASCs
in the AP-induced OA mouse model
We reported earlier a significant increase in the percent-
age of lymphocytes from the BALFs of both hASC-treated
groups (AP/AP–hASC and AP/AP–hASC-sST2) late (7
days) at 21 days after the initial AP sensitization step (Fig.
4C). Accordingly, at 18 days after the initial AP sensitiza-
tion step, we noticed a three- to fourfold increase of the IL-2
levels in the BALFs of the hASC-treated groups (AP/AP–
hASC and AP/AP–hASC-sST2) compared with the non-
treated groups (DMSO/SAL–PBS, DMSO/AP–PBS, and
AP/AP–PBS) (Fig. 8A). A more systematic assessment of
the increased presence of lymphocytes in the BALFs of
hASC- and hASC-sST2-treated mice suggested the induc-
tion of an immune response against xenogeneic hASCs re-
gardless of AP sensitization and/or challenge (Fig. 8B). An
independent study confirmed that the significant lymphocyte
boost occurring 1 week after hASC treatment was indeed
induced by the infused hASC xenocells, because a parallel
infusion of syngeneic murine ASCs was unable to raise the
percentage of lymphocytes in the recipient BALFs (Fig.
8C). Moreover, a significant reduction in the percentage of
BALF lymphocytes in the AP/AP–hASC and AP/AP–
hASC-sST2 groups compared with the DMSO/SAL–hASC
and DMSO/SAL–hASC-sST2 groups, respectively, high-
lighted the superior immune evasiveness of activated hASCs
within the proinflammatory AP-induced milieu of the lungs,
respect to hASCs reaching the control (DMSO/SAL), non-
inflamed lungs (Fig. 8B).
Specific immunostaining of the major lymphocyte sub-
populations present in the BALFs uncovered fourfold in-
crease in the CD3 + CD8 + T cell subpopulation from the
hASC-transplanted mice (DMSO/SAL–hASC and AP/AP–
hASC) compared with nontransplanted mice (DMSO/SAL–
PBS and AP/AP–PBS) (Table 2). Nonetheless, a follow-up
of the lymphocyte content in the BALFs of hASC recipient
mice showed that the increased presence of lymphocytes by
day 7 returned toward baseline levels by day 10, indicating
that the immune response elicited by the xenotransplanted
hASCs was transient (Fig. 8D). Further, the weight of the
treated animals, indicative of their overall health, was nor-
malized by day 10 after cell infusion (Fig. 8E).
FIG. 6. Airway hyperreactivity (AHR) to methacholine in the OA mouse model. AHR expressed as resistance (R) and
elastance (E) was measured at day 16 (A) and day 21 (B) after the initial AP sensitization step by the forced oscillation
technique. Left panels show the mean R values – SEM resulting from increased concentrations of methacholine, and the
individual values of the area under the curve (AUC) of R. Right panels show the mean E values – SEM resulting from
increased concentrations of methacholine, and the individual values of the AUC of E. Experimental groups are at days 16
and 21: DMSO/SAL–PBS, DMSO/AP–PBS, AP/AP–PBS, AP/AP–hASC, and AP/AP–hASC-sST2, plus at day 21 only:
DMSO/SAL–hASC and DMSO/SAL–hASC-sST2 (n = 4–7 mice per group). *P < 0.05, **P < 0.01, and ***P < 0.001
compared with AP/AP–hASC and AP/AP–hASC-sST2 groups; #P < 0.001 compared with the AP/AP–hASC-sST2 group.
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Discussion
This study demonstrates that the intravenous administra-
tion of hASCs has a therapeutic action in established OA
pathology, restoring the basal levels of both neutrophils in
BALF and total IgE in serum, resolving the AHR, and at-
tenuating early lung remodeling.
Recent reports have demonstrated the anti-inflammatory
potential of MSCs in several murine asthma models induced
by high-molecular-weight allergens (ovalbumin, ragweed,
and aspergillus hyphal extract) [11,13,22–28] and in a
low-molecular-weight, toluene diisocyanate (TDI)–induced
asthma model [14]. However, in most of these models, the
MSCs were administered preventively, that is, during the
immunization phase or concomitantly with the induction of
asthma. We transferred the hASCs to the mice 24 h after AP
challenge, when the main pathological features of OA had
already developed [16], which increases the therapeutic
window for hASC intervention and, therefore, their clinical
potential.
The immediate consequence of systemic hASC adminis-
tration at the molecular level was the activation of an im-
mune modulatory profile in these cells upon reaching the
proinflammatory context of the AP-induced asthmatic lung.
This was characterized by early upregulation of ICAM-1, a
critical adhesion molecule involved in cell–cell contact–
mediated immune regulation [20], and further overex-
pression of immunosuppressive molecules such as COX-2,
responsible for the paracrine release of prostaglandin E2
[21]. The therapeutic potential of hASCs is related to their
immediate anti-inflammatory and immunomodulatory ac-
tions [17,29], which indirectly influence epithelial repair and
regeneration of the injured lungs, instead to their intrinsic
regenerative potential, because of their limited engraftment
and transient presence in the hASC-infused mouse lungs.
A very recent study in a mouse model of OVA-induced
FIG. 7. Lung histopathology in the mouse OA model. Histological evaluation of the therapeutic potential of hASC and
hASC-sST2 in murine OA at 21 days after the initial AP sensitization step. Representative images of hematoxylin-and-
eosin-stained, 4-mm lung sections are shown at low (upper panels) and high (lower panels) magnification. AP/AP, AP-
sensitized and -challenged, untreated mice; AP/AP–hASC, AP-sensitized and -challenged, hASC-treated mice; AP/AP–
hASC-sST2, AP-sensitized and -challenged, hASC-sST2-treated mice; DMSO/SAL, control noninduced, untreated mice
(n = 4–7 mice per group). In the left panels and denoted by arrows, AP/AP mice show a marked hyperemia, moderate
leukostasis in the middle-size vessels, and hyperplasia/hypertrophy of the peribronchial musculature, when compared with
the mild changes present in the AP/AP–hASC and AP/AP–hASC-sST2 mice. Scale bars = 20mm. Color images available
online at www.liebertpub.com/scd
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allergic asthma has shown that hASCs activate the pre-
dominant effectors in the pulmonary system, alveolar mac-
rophages, providing a compelling mechanism for their
durable effects despite limited engraftment [27].
Unlike most Th2-driven and eosinophil-mediated classi-
cal asthma models, we assessed the anti-inflammatory effect
of hASCs in an atypical AP-induced and neutrophil-mediated
asthma context, demonstrating baseline neutrophil levels
in the BALFs from hASC-treated mice early after AP
challenge. Accordingly, a recent report also highlights the
anti-inflammatory effects of bone-marrow-derived MSCs
decreasing neutrophils and, to a lesser extension, eosino-
phils, in an experimental TDI-induced OA model [14].
These results underlay the plasticity of MSCs depending
on the inflammatory context in which they are introduced.
Moreover, we have confirmed the outcome of another
atypical trait from the AP-based OA murine model: the
preservation of BALF’s total immune cell counts despite AP
sensitization and challenge [16]. It has been shown that
dermal exposure leads to respiratory tract sensitization, and
several groups have reported in mice that the magnitude of
respiratory responses to inhaled isocyanates (an analogous
low-molecular-weight chemical OA inducer) depends on
Table 1. Histopathological Scoring of Lung
Injury in the Ammonium-Persulfate-Induced










DMSO/SAL–PBS + / - - -
DMSO/AP–PBS + / - - -
AP/AP–PBS +++ +++ +++
AP/AP–hASC + + +
AP/AP–hASC-sST2 + + / - +
aExperimental groups are DMSO/SAL- PBS, DMSO/AP–PBS,
AP/AP–PBS, AP/AP–hASC, and AP/AP–hASC-sST2.
DMSO, dimethylsulfoxide; SAL, saline; PBS, phosphate-buff-
ered saline; AP, ammonium persulfate; hASC, hASCs overexpres-
sing EGFP; hASC-sST2, hASCs overexpressing EGFP and sST2.
Histopathological scoring relied on the examination of 10 different
lung tissue sections/mouse from four animals per group by a blinded
expert pathologist.
- , negative; + , mild; ++ , moderate; +++ , severe.
FIG. 8. Immunogenicity of xenogeneic hASCs in the mouse background. (A) IL-2 levels in the BALFs measured by
multiplex ELISA at day 18 after the initial AP sensitization step (n = 3–5 mice per group). Experimental groups are DMSO/
SAL–PBS, DMSO/AP–PBS, AP/AP–PBS, AP/AP–hASC, and AP/AP–hASC-sST2. *P < 0.05 compared with the DMSO/
SAL–PBS and DMSO/AP–PBS groups. (B) Percentage of lymphocytes in the BALFs evaluated at day 21 after the initial
AP sensitization step using Diff-Quick-stained cytospin preparations. Experimental groups are DMSO/SAL–PBS, DMSO/
SAL–hASC, and DMSO/SAL–hASC-sST2; DMSO/AP–PBS, DMSO/AP–hASC, and DMSO/AP–hASC-sST2; AP/AP–
PBS, AP/AP–hASC, and AP/AP–hASC-sST2. Values are means – SDs (n = 5–7 mice per group). **P < 0.01 and
***P < 0.001 compared with the DMSO/SAL–PBS, DMSO/AP–PBS, and AP/AP–PBS groups. #P < 0.05 compared with the
DMSO/SAL–hASC and DMSO/SAL–hASC-sST2 groups. (C) Percentage of lymphocytes in the BALFs at 7 days after
intravenous infusion of nonmanipulated syngeneic mouse (mASC) or xenogeneic human adipose-tissue-derived mesen-
chymal stem cells, either nonmanipulated (hASC), or genetically engineered to overexpress EGFP (hASC-EGFP). Control:
PBS-injected mice. **P < 0.01 and ***P < 0.001 compared with the control PBS group. (D) Dynamics of the percentage of
lymphocytes in the BALFs of hASC-treated mice. (E) Weight evolution of mice treated with the above ASC types.
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prior frequency and concentration of dermal sensitization
[30–32]. Relatedly, we found no statistical differences in IL-
13 and IFN-g cytokine levels measured in the BALFs re-
gardless of AP-mediated asthma induction. In fact, in a
preceding report establishing the AP-mediated OA model,
significant differences in cytokine levels among the AP-
sensitized and -challenged group and the control non-
sensitized and/or unchallenged groups were found only in
the undiluted supernatants of in-vitro-cultured auricular
lymphocytes [16]. To note, the slightly increased, although
nonsignificant, level of IL-6 found early after AP challenge
only in the BALFs of the asthmatic untreated mice might
suggest the involvement of the IL-17 axis in the AP-induced
OA phenotype. IL-6 has recently emerged as main regulator
of the differentiation and function of Th17 cells [33]. Thus,
further research is needed to confirm the occurrence of
Th17-driven airway inflammation in our AP-induced neu-
trophilic asthma model and its therapeutic reduction by
hASCs, analogously to other recently reported Th17-driven
neutrophilic asthma models [28].
On the other hand, the involvement of IgE to the patho-
genesis of OA induced by high-molecular-weight agents has
been well defined, although its contribution to persulfate-
induced OA is still unclear. It has been recently shown that
in vivo intranasal challenge with AP in sensitized mice leads
to an immediate increase in total serum IgE [16]. Here we
revealed that hASC treatment at 24 h after AP inhalation,
when there is already a significant increase of IgE levels
[16], was able to revert IgE production to basal levels. The
mechanisms by which IgE normalization is achieved are not
well understood, although the immune regulatory actions of
hASCs inhibiting B cell proliferation, differentiation to an-
tibody secreting cells, and chemotaxis may play a pivotal
role [34].
Further, AP-induced asthmatic mice exhibited a marked
hyperemia with polymorphonuclear cell infiltrates and
thickening of the peribronchial musculature. In contrast,
pulmonary histology of hASC-treated mice revealed a sig-
nificant reduction or even absence of asthmatic pathology,
likely due to both paracrine anti-inflammatory and indirect
‘‘regenerative’’ actions of hASCs, administered after the
entire inflammatory response was triggered and, hence, once
the remodeling of the airways was initiated.
One of the most relevant symptoms of asthma is the ex-
istence of AHR to different stimuli such as methacholine.
There are several studies that have analyzed the effect of
MSCs on the AHR in mouse asthma models [see, for ex-
ample, 14,21,35]. Nearly all of them performed the analysis
2 days after asthma induction. In our study, hASC-treated
animals developed neither airway resistance nor airway
elastance in response to methacholine compared with un-
treated animals at both 2 and 7 days after AP-mediated
asthma induction. This observation is clinically relevant
because a single hASC administration enabled the mainte-
nance of lung unresponsiveness for at least 1 week, which
demonstrates the therapeutic utility of hASCs abolishing
inflammation, preventing early lung remodeling, and, con-
sequently, resolving AHR [36]. Nevertheless, a more com-
prehensive airway function study will be needed to assess
additional parameters, such as upper airway resistance (Rn),
tissue damping (G), and tissue elastance (H), allowing to
distinguish central and peripheral respiratory mechanics and
to provide information about the heterogeneity of the re-
spiratory response in the AP-induced OA model.
To assess whether inhibiting IL-33 could further con-
tribute to the therapeutic potential of the hASCs in our AP-
induced OA model, we engineered these cells to overexpress
sST2, the soluble decoy for IL-33 (hASC-sST2). Although
hASC-sST2-based therapy was able to prevent IL-33 in-
duction, the fact that unmodified hASCs already resolved
the principal features of the asthmatic pathology in our
model would explain the minor enhancement of the bene-
ficial effect observed after hASC-sST2 administration. Thus,
additional blockade of the IL-33-T1/ST2 pathway by sus-
tained overexpression of sST2 from the engineered hASCs
might be able to abrogate the persistence of AHR, as sug-
gested recently using either this decoy receptor, a mono-
clonal antibody against IL-33 [37], or a monoclonal
antibody against T1/ST2 [38]. It remains to be seen whether
hASC-sST2 would be able to further extend the therapeutic
benefit provided by unmodified hASCs at later time points
after AP challenge.
Finally, a significant rise in CD3 + T cell numbers was
observed uniquely in the BALF of the hASC- and hASC-
sST2-treated animals up to day 7 after treatment regardless
of asthma induction, with an increased presence of CD3 +
CD8 + T cells, considered to have a major role in graft
rejection [39]. In fact, a recent study has shown that allo-
geneic ASCs are susceptible for lysis by both cytotoxic
CD8 + T cells and NK cells [40]. This suggests the oc-
currence of a host immune response against xenogeneic
hASCs. However, this response was transient and did ap-
pear to compromise neither the health of the treated mice
nor the therapeutic potential of hASCs. We and others have
demonstrated the effectiveness of human ASC/MSC infu-
sion within a xenogeneic environment in murine models
of lung injury [13,17,24,27,30,41], although the present
study highlights for the first time the development of a short
host immune response against the infused xenogeneic
cells. Nevertheless, from a clinical standpoint, the immune-
mediated clearance of allogeneic hASCs, particularly ge-
netically engineered hASCs, in the treated lungs should
reduce the safety concerns regarding the persistence of these
implanted cells longer than required. Therefore, in several
pathological settings, hASCs may exert therapeutic function
Table 2. Relative Number of BALF
Lymphocyte Subpopulations in the OA Mouse















DMSO/SAL–PBS 0.2 36 11.8 3.1
DMSO/SAL–hASC 5.4 28.6 50.5 0.6
AP/AP–PBS 0.5 44.9 21.4 2.1
AP/AP–hASC 8.8 29.9 48.5 0.6
aThe percentage of the different lymphocyte subpopulations in
the pooled BALFs from 10 mice per group receiving an intravenous
injection of 1 · 106 hASCs or PBS was assessed 6 days later by flow
cytometry with CD-specific antibodies.
BALF, bronchoalveolar lavage fluid.
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through a brief ‘‘hit-and-run’’ mechanism, although in
chronic conditions protecting these cells from immune de-
tection and prolonging their persistence in vivo may im-
prove clinical outcomes and prevent patient sensitization
toward donor antigens.
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